Sudhakar Tummala^1,2,*, Sajjad Hussain Chauhdary³, Vikash Singh⁴, Roshan Kumar⁵, Seifedine Kadry⁶, Jungeun Kim^7,*

CMES-Computer Modeling in Engineering & Sciences, Vol.144, No.3, pp. 3585-3605, 2025, DOI:10.32604/cmes.2025.069731 - 30 September 2025

Abstract Lightweight deep learning models are increasingly required in resource-constrained environments such as mobile devices and the Internet of Medical Things (IoMT). Multi-head convolution with channel attention can facilitate learning activations relevant to different kernel sizes within a multi-head convolutional layer. Therefore, this study investigates the capability of novel lightweight models incorporating residual multi-head convolution with channel attention (ResMHCNN) blocks to classify medical images. We introduced three novel lightweight deep learning models (BT-Net, LCC-Net, and BC-Net) utilizing the ResMHCNN block as their backbone. These models were cross-validated and tested on three publicly available medical image datasets:… More >

Neha Raina¹, Radha Rani², Mahika Kanojia², Avril Mathias³, Keshav Raj Paudel^4,*, Ashish Garg⁵, Hardeep Singh Tuli⁶, A. T. M. Mijanur Rahman⁷, Vetriselvan Subramaniyan⁸, Madhu Gupta^2,*

Oncology Research, Vol.33, No.10, pp. 2787-2831, 2025, DOI:10.32604/or.2025.066624 - 26 September 2025

Abstract Breast cancer is among the most prevalent cancers in females globally and has the highest mortality rate. The emergence of pharmacologic resistance in breast cancer is a significant challenge for researchers in the pursuit of effective treatment. Investigations in cancer nanotechnology have been transformed by the advancement of smart polymers, lipids, and inorganic materials. Research is now being conducted in the field of innovative nano-pharmaceutical formulations aimed at enhancing the efficacy and durability of chemotherapy. Nanotechnology-based delivery systems are beneficial for combating breast cancer due to theranostic applications, augmented drug encapsulation, decreased degradation, and minimal… More >

Chuansheng Yang¹, Xiaoling Zhou^2,3, Ling Luo³, Zirun Luo⁴, Kaiming Fan^5,*, Chenglai Xia^2,3,*

Oncology Research, Vol.33, No.10, pp. 3065-3076, 2025, DOI:10.32604/or.2025.066058 - 26 September 2025

Abstract Objectives: Novel drug delivery systems have been designed to enhance local drug concentrations while reducing side effects conducive to improved breast cancer treatment outcomes. This study aimed to identify the anti-cancer function of zeolite imidazole ester-based material loaded with camptothecin nanoparticles. Methods: We utilized a zeolitic imidazolate backbone material to fabricate 9-hydroxycamptothecin nanoparticles and investigated their impact on breast cancer cell proliferation. Scanning electron microscopy and Fourier-transform infrared spectroscopy revealed changes in the carrier skeleton of the loaded 9-hydroxyl camptothecin, characterized by a reduction in surface smoothness, accompanied by slight collapses and folds on the… More >

Hailong Li^1,#, Wen Ouyang^2,#, Yiyin Long¹, Yun Peng¹, Ziyi Liu¹, Qi Zhou¹, Rong Xu^1,*, Wei Du^1,*

Oncology Research, Vol.33, No.9, pp. 2549-2571, 2025, DOI:10.32604/or.2025.065050 - 28 August 2025

Abstract Background: The study aimed to explore the clinical value of mitochondrial ribosomal protein L18 (MRPL18) in breast cancer. Methods: Multiple databases were used to validate the expression of MRPL18. The prognostic impact and predictive value of MRPL18 were evaluated by using predictive models. Protein-protein interaction (PPI) networks were constructed by using GeneMANIA. Enrichment analysis is used to explore the signaling pathway regulated by MRPL18. Cell counting kit-8 (CCK-8) assays, colony formation, migration assays, flow cytometry, and xenograft models were employed to evaluate the role of MRPL18 in tumor progression. The immune response of MRPL18 was More >

Xizhou Zhang^1,#, Zetao Zhang^1,#, Jianguang Lin², Jiarong Yi³, Xuxiazi Zou³, Jikun Feng³, Guangsheng Huang¹, Bingfeng Chen¹, Junxi Long¹, Fengjia Wu³, Feng Ye^3,*, Haoming Wu^1,*

Oncology Research, Vol.33, No.9, pp. 2529-2547, 2025, DOI:10.32604/or.2025.065029 - 28 August 2025

Abstract Background: Breast cancer remains a leading cause of morbidity and mortality among women worldwide, with significant geographic disparities in its impact. While human epidermal growth factor receptor 2 (HER2)-targeted therapies, such as trastuzumab, have improved outcomes for HER2-positive breast cancer, challenges like therapy resistance persist, highlighting the need for novel treatments. Recent developments in antibody-drug conjugates (ADCs), particularly disitamab vedotin (RC48), show promising efficacy in targeting both HER2-positive and HER2-low expression tumors, warranting further investigation through real-world studies to assess its broader clinical applicability. Method: This retrospective, multicenter observational study evaluated the real-world efficacy and… More >

Akari Fukumoto, Satoru Matsuda^*

Oncology Research, Vol.33, No.9, pp. 2205-2219, 2025, DOI:10.32604/or.2025.062810 - 28 August 2025

Abstract The non-coding RNAs (ncRNAs) are a family of single-stranded RNAs that have become recognized as crucial gene expression regulators in normal and cancer cell biology. The gut microbiota, which consists of several different bacteria, can actively contribute to the regulation of host metabolism, immunity, and inflammation. Roles of ncRNAs and gut microbiota could significantly interact with each other to regulate the growth of various types of cancer. In particular, a causal relationship among ncRNAs, gut microbiota, and immune cells has been shown for their potential importance in the development of breast cancer. Alteration of ncRNA More >

Alejandro Javier Español^1,2,*, Yamila Sanchez¹, Sofia Volpi²

BIOCELL, Vol.49, No.8, pp. 1449-1480, 2025, DOI:10.32604/biocell.2025.068034 - 29 August 2025

Abstract Background: Triple-negative (TN) breast cancer, the most aggressive subtype of breast cancer, is usually treated with high doses of paclitaxel (PX), which induces resistance. To prevent this adverse effect, metronomic chemotherapy based on administering low doses of PX plus carbachol (Carb), a muscarinic acetylcholine receptor (mAChR) agonist, has emerged as an alternative. Other acetylcholine receptors also present in breast tissue are nicotinic ones. When activated by nicotine (Nic), these receptors can decrease the effectiveness of conventional chemotherapy. However, whether metronomic chemotherapy with PX and Carb is affected by Nic has not yet been described. This… More >

Roseline Oluwaseun Ogundokun^*, Pius Adewale Owolawi, Chunling Tu

CMC-Computers, Materials & Continua, Vol.84, No.3, pp. 4869-4885, 2025, DOI:10.32604/cmc.2025.064944 - 30 July 2025

Abstract Breast cancer is among the leading causes of cancer mortality globally, and its diagnosis through histopathological image analysis is often prone to inter-observer variability and misclassification. Existing machine learning (ML) methods struggle with intra-class heterogeneity and inter-class similarity, necessitating more robust classification models. This study presents an ML classifier ensemble hybrid model for deep feature extraction with deep learning (DL) and Bat Swarm Optimization (BSO) hyperparameter optimization to improve breast cancer histopathology (BCH) image classification. A dataset of 804 Hematoxylin and Eosin (H&E) stained images classified as Benign, in situ, Invasive, and Normal categories (ICIAR2018_BACH_Challenge) has… More >

Oncology Research Editorial Offfce

Oncology Research, Vol.33, No.8, pp. 2175-2175, 2025, DOI:10.32604/or.2025.070131 - 18 July 2025

Abstract This article has no abstract. More >

Zhun Yu^1,2, Jie Wang^1,2, Guoping Xu^1,2,*

Oncology Research, Vol.33, No.8, pp. 2013-2035, 2025, DOI:10.32604/or.2025.061757 - 18 July 2025

Abstract Objectives: Triple-negative breast cancer (TNBC) presents a major treatment challenge due to its aggressive behavior. The dysfunction of the Golgi apparatus (GA) contributes to the development of various cancers. This study aimed to utilize GA-related genes (GARGs) to forecast the prognosis and immune profile of TNBC. Methods: The data were downloaded from The Cancer Genome Atlas (TCGA) database, including 175 TNBC and 99 healthy samples. The differentially expressed GARGs (DEGARGs) were analyzed using the TCGA biolinks package. The patients with TNBC were classified into two clusters utilizing the ConsensusClusterPlus package according to prognosis-related DEGARGs, followed by… More >